Jump to Main Contents
ncc en

Home > Information > What's New 2022

What's New 2022

Dec. 8, 2022
Asian multicenter prospective study (CHOICE study) to elucidate the pathogenesis of cholangiocarcinoma(including FGFR2-rearranged) launched
Nov. 18, 2022
Researchers from National Cancer Center on ‘Highly Cited Researchers 2022’ List
Nov. 4, 2022
Cancer Genomic Medicine in Japan Engages International Interest - Article Published on Cancer Discovery
Nov. 2, 2022
Yusuke Okuma has been awarded “Best of the AACR Journals”
Oct. 7, 2022
Fusion genes as drug resistance in EGFR mutant lung cancer
Sep. 27, 2022
Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform
Sep. 27, 2022
Study pinpoints origin of pediatric brain tumour and shows it may be preventable
Aug. 24, 2022
Large scale clinical trial for Neuroendocrine Carcinoma (NEC), a rare and refractory cancer establishes current chemotherapy for advanced and recurrent cancer as standard therapy
Aug. 8, 2022
American Society of Hematology Confers Akihide Yoshimi the Global Research Award
Aug. 8, 2022
Akihide Yoshimi, Section Head of Cancer RNA Research Unit, Research Institute was Awarded the ASH Global Research Award 2022
Aug. 5, 2022
Prospective Cohort Study demonstrates ESD as primary choice of treatment for neoplasia of over 2cm
Aug. 4, 2022
Approximately 43,000 individual patient data of clinical trials with colorectal cancer in Asia and the West shared
Aug. 1, 2022
Supporting Cancer Registration in Viet Nam
Aug. 1, 2022
First Japanese and Asian Chairperson of IARC Scientific Council
Dr. Manami Inoue, Chief – Institute for Cancer Control, NCC
Contributing to Global Cancer Control
Jul. 21, 2022
Joint Research with IARC Identifying associations between lifestyle risk factors and the prognosis of cancer survivors
Jul. 11, 2022
Franco-Japanese immuno-oncology webinar 4st session held
Jul. 1, 2022
Utility of gene panel testing for comprehensive genomic profiling of blood cancers demonstrated
Jun. 29, 2022
Health and Medical Delegation from Viet Nam visited
Jun. 22, 2022
Projected Cancer Statistics
Jun. 14, 2022
Cancer Statistics in Japan; Table download
Jun. 8, 2022
Virtual Meeting with Peking University First Hospital, Celebrating the Conclusion of Memorandum of Understanding
May 25, 2022
Franco-Japanese immuno-oncology webinar 3rd session held
May 25, 2022
Cooperation with the U.S. National Cancer Institute welcomed by Japan-US leaders in joint statement- role of National Cancer Center highlighted
Apr. 12, 2022
Hiroyoshi Nishikawa honored with a prestigious Commendation from the Minister of Education, Culture, Sports, Science and Technology
Apr. 11, 2022
Mar. 25, 2022
Franco-Japanese immuno-oncology webinar 2st session held
Mar. 18, 2022
Aberrant activation of cell cycle-related kinases in uterine leiomyosarcoma
Mar. 3, 2022
Discovery of splicing vulnerability and novel therapy in RAS Q61 cancers -Nature-
Feb. 21, 2022
Memorandum of Understanding signed with Peking University First Hospital
Feb. 1, 2022
Recruitment of Postdoctoral Fellow
Feb. 1, 2022
Virtual Meeting with Tata Memorial Centre of India, Celebrating the Conclusion of Memorandum of Understanding
Jan. 28, 2022
Franco-Japanese immuno-oncology webinar 1st session held
Jan. 28, 2022
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
Jan. 18, 2022
Tatsuhiro Shibata awarded Princess Takamatsu Cancer Research Fund Prize
Jan. 11, 2022
Joint Statement Announced upon the visit by Prime Minister of Viet Nam
Jan. 6, 2022
Franco-Japanese immuno-oncology webinar series